Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc.verified

BCLI

Price:

$0.61

Market Cap:

$6.73M

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment o...[Read more]

Industry

Biotechnology

IPO Date

2003-10-07

Stock Exchange

NASDAQ

Ticker

BCLI

The PE Ratio as of December 2025 (TTM) for Brainstorm Cell Therapeutics Inc. (BCLI) is -0.43

According to Brainstorm Cell Therapeutics Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.43. This represents a change of -34.31% compared to the average of -0.65 of the last 4 quarters.

Brainstorm Cell Therapeutics Inc. (BCLI) Historical PE Ratio (quarterly & annually)

How has BCLI PE Ratio performed in the past?

The mean historical PE Ratio of Brainstorm Cell Therapeutics Inc. over the last ten years is -5.39. The current -0.43 PE Ratio has changed 697.72% with respect to the historical average. Over the past ten years (40 quarters), BCLI's PE Ratio was at its highest in in the December 2017 quarter at 67.06. The PE Ratio was at its lowest in in the September 2020 quarter at -29.36.

Quarterly (TTM)
Annual

Average

-5.39

Median

-5.06

Minimum

-15.01

Maximum

1.04

Brainstorm Cell Therapeutics Inc. (BCLI) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Brainstorm Cell Therapeutics Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 57.63%

Maximum Annual PE Ratio = 1.04

Minimum Annual Increase = -213.27%

Minimum Annual PE Ratio = -15.01

Quarterly (TTM)
Annual
YearPE RatioChange
20241.04-213.27%
2023-0.92-63.05%
2022-2.48-58.35%
2021-5.9523.48%
2020-4.822.33%
2019-4.71-11.15%
2018-5.30-64.71%
2017-15.0157.63%
2016-9.5252.67%
2015-6.24-27.43%

Brainstorm Cell Therapeutics Inc. (BCLI) Average PE Ratio

How has BCLI PE Ratio performed in the past?

The current PE Ratio of Brainstorm Cell Therapeutics Inc. (BCLI) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-0.79

5-year avg

-2.62

10-year avg

-5.39

Brainstorm Cell Therapeutics Inc. (BCLI) PE Ratio vs. Peers

How is BCLI’s PE Ratio compared to its peers?

Brainstorm Cell Therapeutics Inc.’s PE Ratio is greater than NeuroSense Therapeutics Ltd. (-3.52), less than Matinas BioPharma Holdings, Inc. (-0.23), greater than Adial Pharmaceuticals, Inc. (-0.90), greater than Cardio Diagnostics Holdings, Inc. (-0.85), less than HCW Biologics Inc. (-0.21), less than Impact BioMedical Inc. (-0.15), less than Acurx Pharmaceuticals, Inc. (-0.00), greater than VYNE Therapeutics Inc. (-0.48), greater than Addex Therapeutics Ltd (-0.90), greater than BioCardia, Inc. (-1080.61),

Build a custom stock screener for Brainstorm Cell Therapeutics Inc. (BCLI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Brainstorm Cell Therapeutics Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Brainstorm Cell Therapeutics Inc. (BCLI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Brainstorm Cell Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Brainstorm Cell Therapeutics Inc.'s PE Ratio?

How is the PE Ratio calculated for Brainstorm Cell Therapeutics Inc. (BCLI)?

What is the highest PE Ratio for Brainstorm Cell Therapeutics Inc. (BCLI)?

What is the 3-year average PE Ratio for Brainstorm Cell Therapeutics Inc. (BCLI)?

What is the 5-year average PE Ratio for Brainstorm Cell Therapeutics Inc. (BCLI)?

How does the current PE Ratio for Brainstorm Cell Therapeutics Inc. (BCLI) compare to its historical average?